These insights culminated in the BEACON CRC trial, a pivotal phase III study demonstrating that dual therapy with encorafenib (a selective BRAF inhibitor) and cetuximab (an EGFR-targeting antibody) significantly improved OS (8.4 vs. 5.4 months) compared with standard chemotherapy in chemotherapy-pretreated patients (>1 line of treatment). This evidence concerns the gene BRAF and colorectal carcinoma.